卫克泰为数百万癫痫患者带来治疗新选择

Epilepsy is a neurological disease characterized by highly synchronous abnormal discharges of nerve groups. The global incidence rate is about 50/100,000 people, the prevalence rate is 4-12/1000 people, and at least 50-70 million people are affected by it. At present, drugs are still the first choice for anti-epileptic treatment. Some patients with epilepsy even need to take drugs for life. Most of them can be effectively controlled. However, 30% to 40% of patients have epileptic seizures that are not controlled by single drugs or combinations of drugs, and eventually form refractory epilepsy. It is a highly selective, non-competitive AMPA receptor antagonist. By acting on postsynaptic membrane AMPA receptors, it non-competitively inhibits glutamate activity, thereby reducing neuronal excitability, thereby exerting an anti-epileptic effect. It must be said that Weiketai has brought new treatment options to millions of epilepsy patients.

Liguori et al. observed the efficacy and tolerance of the first application of Vectin and levetiracetam in epilepsy patients with secondary generalized seizures. They collected data on 15 patients who received Vectin and 26 patients who received levetiracetam. During the 3-month and 12-month follow-up, patients who received Vectin had fewer adverse reactions than those who received levetiracetam, and Vectin was better tolerated than levetiracetam.

In 2012, the U.S. FDA approved the oral tablets of Vecta to be marketed and can only be used as an add-on treatment for patients with partial epileptic seizures aged 12 years and above. Three years later, the FDA expanded its indications and approved it for the additional treatment of epilepsy patients 12 years of age and older with primary generalized tonic-clonic seizures. In April 2016, the FDA approved its oral suspension for treatment, with the same indications as tablets. The following year, the drug was approved as a monotherapy for the treatment of partial-onset seizures in patients 12 years of age and older. In 2018, the FDA further expanded its indications and approved its use for the treatment of partial epileptic seizures in children aged 4 years and above.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.